Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in 60 Healthy Tubal-ligated Women Aged 18 to 45 Years Investigating the Pharmacodynamic Effects of 5 Different Doses (0.1 - 5 mg) BAY1002670 After Daily Oral Administration Over 84 Days

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in 60 Healthy Tubal-ligated Women Aged 18 to 45 Years Investigating the Pharmacodynamic Effects of 5 Different Doses (0.1 - 5 mg) BAY1002670 After Daily Oral Administration Over 84 Days

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs Vilaprisan (Primary)
  • Indications Uterine leiomyoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 10 Oct 2018 Results of an exploratory analysis presented at the American Society for Reproductive Medicine Scientific Congress 2018
    • 24 Mar 2015 Results of pharmacodynamic study will be presented at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting, according to Bayer HealthCare media release.
    • 30 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top